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Summary of main points made at the meeting
1. Large trials (with greater than 1,000 patients) are
necessary to ensure a reasonable power of detecting the
small improvements in survival that may result from a
change in cancer treatment. Such improvements,
although, small, are humanly worthwhile and therefore
important to determine.
2. Too many past and current trials have recruited
insufficient numbers to give adequate power of detecting
the differences that could have reasonably been expected
on the basis of prior clinical knowledge. The number of
patients at present entered in trials is only a few per cent
of the eligible patient population.
3. Possible reasons for low recruitment are:
(a) The question being addressed does not seem to most
clinicians to be very important.
(b) Complexity of trial design, forms and procedures.
(c) Difficulty of carrying out complex treatment
schedules in non-teaching hospitals.
(d) Toxicity of some treatments being tested.
(e) Limiting recruitment to teaching hospitals.
(f) Lack of incentives for clinicians to participate.
(g) Problems of obtaining informed consent from
patients.
4. Possible ways of overcoming these difficulties are:
(a) Identifying important questions in oncology and
concentrating trials on these questions.
(b) Keeping all trial procedures and forms as simple as
possible.
(c) Spreading recruitment to non-teaching hospitals and,
if necessary, to Europe and further afield.
(d) Making participation in trials worthwhile for
clinicians by frequent interesting and lively meetings
of participants, and regular communication from the
Trial Centre in the form of newsletters and visits.
(e) Resolving the problems of obtaining informed consent
by giving priority to what is really in the best interest
of the patient, rather than to the satisfaction of a
rigid ethico-legal formula. There should be no
difference in standard between the informed consent
required from a patient in a trial and the informed
consent to treatment that a clinician would normally
obtain from a patient not in a trial.
5. Some small trials (200 to 1,000 patients) are worthwhile if
the end-point is other than survival, a high event rate is
anticipated or a large benefit can reasonably be expected.
Such trials may also be acceptable when the disease is
comparatively rare, or the treatments being tested can
only be carried out in a few specialist centres. If trials of
this size are being considered, funding bodies should take
into account similar trials that may be taking place
elsewhere, the results of which might be combined in an
overview.
6. In setting up a trial, whether small or large, a careful
study should be made of the objective evidence relating to
the anticipated difference between the responses to the
treatments being compared. If such evidence is not
available, a systematic study should be made of expert
opinion on the expected treatment difference.
7. The Trial Coordinator, who need not be medically
qualified, is vital to the success of a trial. To recruit
persons of suitable calibre, a proper career structure needs
to be established.
Proceedings
L. Freedman (Cambridge) opened the morning session with a
paper on Trial Size Needs. He posed three questions: (1) Do
we need more large simple randomised trials in cancer
('large' meaning greater than 1,000 patients)? (2) Should we
ever settle for moderate sized (200-1,000 patients)
randomised trials? (3) What should be the statistician's role
in individual decisions?
Approximately 1,000 patients are needed to have a 90%
power of detecting a 10% improvement in survival rates at
the 5% level of significance. Hence a large trial is needed if
only a modest difference is expected. Other necessary
conditions for large trials are that an important question is
to be answered in a relatively common condition, there can
be a simply-measured endpoint and the treatments compared
can be widely applicable. There are many common cancers
involving thousands of patients annually in the UK, but at
present only about 2% of these patients are entered into
trials (except for breast cancer where the figure is about
8%). There are simply-measured endpoints such as survival,
and only modest differences are to be expected. There are
therefore situations which can justify large trials and the
need is for statisticians and clinicians to identify them. An
example is the value of different forms of adjuvant therapy
in colorectal cancer.
Moderate sized trials can be justified when there is a
clinically meaningful endpoint that is very sensitive to
treatment effect, or a very high event rate so that, for
example, 500 patients had 500 events, or when an improve-
ment of greater than 10% in survival or recurrence-free rates
can realistically be expected. One may also have to settle for
moderate sized trials when the condition is uncommon, or
the treatments are not widely applicable.
The statistician should play an active role in assessing the
likely difference to be expected between treatments. This can
be done through overviews of other similar trials and
previous non-randomised studies, and by assessing expert
opinion.
The statistician can also prevent confusion between the
smallest clinically worthwhile difference (SCWD) and the
'alternative hypothesis'. The role of the SCWD should be to
modify the null hypothesis, and this more realistic null
hypothesis, together with the prior distribution, could be
used to calculate the predicted probability of a definite
clinical recommendation emerging from a trial with a given
number of patients. One might then establish a rule for
funding trials such as, for example, fund if more than X% of
the prior distribution is further than 10% away from the null
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hypothesis, where X would depend on the availability of
funds and the competition and should probably be between
25 and 55%.
In the discussion, J. Peto (Sutton) questioned whether it
was realistic in trials of cancer therapy ever to plan a trial on
the basis of an expected difference greater than 10%, since
most trials, so far, had found differences less than this
figure. Mr Freedman felt that this was too pessimistic a view
to take, particularly of new experimental treatment.
The second paper was by M. Buyse (EORTC Data Center,
Brussels) on the subject of Trial Size - Current Practice. He
first discussed the determinants of trial size in terms of
medically worthwhile and plausible treatment effect, patient
availability and other extraneous factors. What is medically
worthwhile depends on survival expectancy, treatment
toxicity, ease of use of the treatment and disease incidence.
What is plausible must depend on past experience with
related treatments, the biological rationale for the expected
effect, and also possibly on epidemiological data. If the
plausible effect is less than the worthwhile effect, then a trial
may not be worth doing.
Mr Buyse then reviewed trial size in 47 EORTC phase III
trials where the patient entry had closed. A comparison of
planned numbers versus achieved numbers showed no clear
evidence for either under- or over-achievement, but planned
sizes covered a wide range from 800 down to 60.
Most of the trials showed no convincing evidence of a
treatment benefit in terms ofsurvival time but in many cases
the power of the trials had been low and they could not,
therefore, have been expected to show evidence of a benefit
that might have been considered plausible.
D. Spiegelhalter (Cambridge) opened the discussion by
wondering whether clinicians were grossly optimistic about
the likely size of the treatment effect and whether they
nevertheless were good at making a reasonable guess at
which was the better treatment. It would be interesting to
plot the difference for which there would be a 50% power in
each trial against the observed difference in each trial. A
clear relationship would show how the clinicians' expec-
tations could be translated into a realistic assessment.
J. Peto broadened the discussion to the problem of how to
encourage clinicians to participate in trials by making them
more 'fun' i.e. interesting and rewarding, for the participants.
Some collaborative groups in America have tried to do this
by setting up an interesting research environment for their
trials and having associated studies of prognostic factors,
pharmacological behaviour of drugs, and special subgroups.
We should be trying to do the same in this country.
G. Blackledge (Birmingham) said that Mr Buyse's survey
was not so discouraging. In quite a lot of the EORTC trials
where a null result had been the outcome, this had been
useful in showing that additional treatment of some form
had not been beneficial, and, many patients were now being
spared unnecessary treatment. Mr Buyse replied that
negative trials are useful only if they are large enough to
ensure that treatment effects which may be missed are
smaller than the minimum effects considered to be
worthwhile.
The last speaker in the morning session was R. Peto
(Oxford) on the subject of Clinical Trial Overviews. These
are necessary to pick up effects which are small but
nevertheless very worthwhile. When a number of trials
address the same question you may, by an overview, get a
clear answer to that question. The situation in breast cancer
was fortunate. The NATO trial of adjuvant tamoxifen was
beginning to look promising and the question arose whether
the study should be stopped and the clinicians informed of
the pattern that was emerging. It turned out that there were
36 such trials around the world. When the triallists were
contacted to see if they would submit data for an overview,
practically all of them thought that, while tamoxifen might
be delaying recurrence, it was having no effect on survival.
In fact the overview showed a real improvement in survival
for the tamoxifen treated patients.
Some overviews have shown no difference between treat-
ments. One of the trials assessing the value of post-operative
radiotherapy in breast cancer shows no survival difference
up to 10 years. It is interesting to contrast this with clinical
opinion before the trials and the overview were done. A
survey of all the chapters or papers reviewing the evidence
for the benefit of radiotherapy showed that surgeons tended
to think radiotherapy could be disadvantageous while
radiotherapists tended to think the reverse. Mr Buyse has
carried out an overview of studies examining whether radio-
therapy is of any value in rectal cancer, and the answer
seems to be that there may possibly be an improvement of
about 5%, but it is not statistically significant. We are just
not getting enough patients entered into trials to answer
these important questions. Somehow the numbers entering
trials have to be increased and trials become a part of
routine clinical service. One way of doing this would be to
reduce their complexity both in the method of entering
patients and in the data to be collected.
M. Van Glabekke (Brussels) asked whether more patients
were entered into cardiovascular trials because the treatments
were very much less toxic. Mr R. Peto felt that one answer
to toxicity was to be much more flexible about the treatment
protocols in trials. If one wanted to know if radiotherapy
was of value or not, then accept a wide range of radio-
therapy techniques, so that clinicians could still enter
patients, but give a dose in keeping with their individual idea
of what is acceptable.
Mr Freedman said that the MRC had not primarily
addressed itself to questions in common cancers, where large
trials might be both necessary and worthwhile. Perhaps this
was something we should be trying to get the MRC to do.
Mr R. Peto agreed, but commented that the radiosensitizer
questions were good questions, but the trials were of
inadequate size to provide answers. Mr Freedman disagreed
with this. The glioma trial with 400 patients showed very
clearly that the radiosensitizer was not improving survival
to the extent that had been expected. The trials of
misonidazole were also conducted in diseases that were not
all that common, stage III carcinoma of the cervix and head
and neck cancer, both these sites being chosen on scientific
grounds because of the ability to monitor local control.
D. Byar (National Cancer Institute) said that the
experience in the USA was not very different from that
reported by Mr Buyse for Europe. In fact the Cancer
Therapy Evaluation Branch of the Treatment Division of the
NCI has been taking a soul-searching look at their own
clinical trial activity, because of criticisms suggesting that
very little had been discovered by the clinical trials pro-
grammes in proportion to the amount of money that had
been spent. The important question is in which situations do
you want these large simple trials and in which situations are
other approaches to research more appropriate. Perhaps the
focus should be on identifying more carefully the questions
that are worth pursuing and then concentrating our effort on
them.
Mr R. Peto wound up the morning session by saying that
trials that have been done in the past have acted as a
considerable restraint upon what people are likely to believe.
A more positive side has been that some trials, such as those
in leukaemia, have helped to show how chemotherapy can
be given optimally. Trials also provide organised series of
patients for centralised study and discussion. The MRC,
EORTC and NCI have put a lot of effort into trials and on
the whole those trials have done more good than harm. We
need to choose a few really good questions where a
moderate difference in survival might well exist, or there is a
difference in toxicity and no difference in survival. If you are
doing a trial, your responsibility is not only to get as many
patients as you can into your own trial, but to be aware of
trials addressing the same question in other countries and to
foster such trials.
The afternoon session was devoted to lessons to be learnt
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and each speaker reported on his experience in trials in a
particular area.
M. Baum (London) considered the breast cancer trials he
had been involved in, the first of which was the CRC
(Kings/Cambridge) trial comparing post-operative radio-
therapy with a watch policy in early breast cancer. There
were four essentials for running a large multicentre trial, a
real Hypothesis, an adequate Organisation, many Patients
and many Events (HOPE). What we need more than
anything else in multicentre trials is hope. He agreed with
Richard Peto that the best hypotheses we should test are
those which are going to help a clinician to resolve his
uncertainties in everyday practice.
When the Kings/Cambridge trial was being planned nearly
20 years ago, the statistical advice given was that if they
wanted to stand a reasonable chance (9 in 10) of detecting a
difference that would be clinically important (about 7%),
they must recruit 2,000 patients. It was realised that to get
these numbers, a large number of ordinary District Hospitals
must be involved. This set the ethos for the group which has
been maintained ever since, that one has to have large
numbers and to go where the patients are, to the District
General Hospitals. One therefore has to have protocols that
are pragmatic in design and which can be conducted in a
busy DGH practice. His group had worked very hard over
the years to simplify protocols and they had now managed
to get a protocol onto credit-card size.
Out of the original group developed the CRC Trials
Centre at the Rayne Institute. It is essential to have a proper
professional organisation with trial coordinators, computing
facilities, programmers, office and secretarial staff. In
Professor Baum's view, their secret weapon had been their
Senior Trials Coordinator, Mrs Joan Houghton, and he
wanted to stress that such people were absolutely vital to the
success of multicentre clinical trials, and that it was essential
for them to have a proper career structure. Liaison with
participating centres involves frequent visits to those centres
and these visits, together with annual or biannual general
meetings, all encourage clinicians to join in trials.
Prof. Baum's group had also over the years made a great
effort towards simplification of data collection sheets. Once
a patient was randomised, clinicians were supplied with a
series of adhesive labels which identified the patient (not by
name) and which could be affixed to tear-off pre-addressed
cards, on which all necessary follow-up information could be
entered.
Regular surveys of clinical practice throughout the country
are carried out to help identify what are the current relevant
questions which should be addressed by clinical trials of
cancer of the breast. A questionnaire in 1980 showed that
there was considerable uncertainty about the use of adjuvant
systemic therapy in early breast cancer and it would be
reasonable to launch a trial with a control arm which had no
such adjuvant therapy. In 1983 a questionnaire identified the
uncertainty over local excision versus simple mastectomy.
However, the resulting two trials, fared very differently.
The adjuvant trial accrued more than 2,000 patients in three
and a half years without any problem, while the breast
conservation trial which addressed a clinically most relevant
question had to be aborted after two and a half years with
less than 200 patients. The reason for its failure was an
ethical one. The biggest problem now facing trial organisers
is the issue of informed consent. We have to persuade
clinicians who are frightened by the procedure of informed
consent that this is an issue which concerns patients out of
trials just as much as those in trials.
R. Peto (Oxford) gave the second paper in the afternoon,
his subject being a current MRC trial in prostate cancer. The
median age of patients is 75, and many patients appear to do
quite well if left untreated, or at least not treated until their
disease causes troublesome symptoms. The question then is
whether one should treat immediately at diagnosis or
whether one should defer treatment until some evidence
emerges that treatment is clearly needed. The best trial that
had so far been done in prostate cancer recruited 2,000
patients throughout the USA and showed a significant
reduction in mortality from prostate cancer in the immedi-
ately treated group, but the difference in overall mortality
was not very different. This result was suggestive, but the
possible benefits of immediate treatment were not accepted
by the British medical profession. Using the USA trial to get
an estimate of the possible effect to be looked for, one could
calculate that about 2,000 patients were needed for a 90%
power. About 50 centres had already started to randomise
when there was criticism both in the press and in Parliament
that patients were being randomised without their full
consent. The trial organisers had said that clinicians should
invite patients to enter into the trial in a way that was
appropriate to the advice from their local ethical committee,
and to give information that was designed with the best
interests of the patient at heart. Only a few hundred patients
have been entered so far, and it seems that the ethical
problem may be one of the main reasons. The trial was
simple, and certainly addressed a question of substantial
interest to the profession. Mr Peto felt that ethical problems
could be a major obstacle to the successful conduct of
clinical trials.
R. Collins opened the discussion by saying that in one
acute myocardial infarction trial (ISIS-2), in which 12,000
patients have been randomised from 400 hospitals, the 50
hospitals in the USA are randomising much slower and have
only entered a few hundred patients. This may well be
because everywhere except in the USA there is either no
consent form or a simple information sheet, whereas in the
USA, the lawyers decided that it was necessary to have a
three-page closely spaced informed consent form, which the
patient is expected to read just after a heart attack, often
when he's just been given diamorphine. The form can take
an hour to go through properly with a patient and this
would appear to have been a major obstacle to random-
isation in the USA.
Mr Peto referred back to the principles laid down by
Bradford Hill about 30 years ago, and his excellent
discussion of informed consent. There are many circum-
stances in which informed consent before randomisation is
not appropriate and the prostate trial is one. To stress to
people that they have cancer, that you can't get rid of that
cancer, that it may kill them and that you are uncertain of
the best treatment is just inhumane. Doctors will answer
questions if they are asked them, but they should not have
to impose miserable depressing information on patients if it
seems humanely inappropriate to do so. What individual
people need is different, and the growing version of informed
consent that is now becoming standard unfortunately takes
no account of these differences. Professor Baum had often
said in this context that there seems to be a double standard:
patients are supposed for ethical reasons to be told things in
clinical trials which one would never dream of telling them
in ordinary clinical practice. This double standard is an
obstacle to trials and often results in inhumane treatment of
the patients in trials.
S. Pocock (London) asked if Mr Peto was arguing that in
the prostate trial there should be no consent or was he
arguing for flexible consent. Mr Peto replied that clinicians
should be able to decide what is appropriate for individual
patients. He quoted Dr Warlow's trial, where clinicians
could either explain the trial before randomisation or they
could ring up for the randomisation, and then explain this
treatment procedure to the patient. For example, if the
patient was allocated to surgery, he would be told that a
study was being undertaken to see if surgery would improve
the treatment of his condition, he would be told what the
treatment and follow-up would involve, and then asked if he
would be willing to enter the study. Dr Pocock said this was
basically the procedure suggested by Zelen, namely that the
patient should be randomised and his consent then obtained
to the treatment he has been allocated.
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experience gained with rectal cancer trials. The first MRC
rectal cancer trial stopped entry in August 1978, with 850
patients entered at a rate of about 250 per year. The trial
compared surgery immediately with pre-operative radio-
therapy of 500cGy in 1 fraction or pre-operative radio-
therapy of 2,000cGy in 10 fractions. At the time of stopping
the trial, the analysis showed no apparent difference between
the groups in terms of survival, etc., but did show the effects
of some prognostic factors. Patients with mobile tumours
pre-operatively had a 48% survival at 5 years compared with
29% for those with tethered tumours. The post-operative
Dukes' classification was also important; Dukes' A 70%
compared with 36% for Dukes' B and C.
Having finished that study, there was debate about
whether there should be a larger dose of radiotherapy used,
whether radiotherapy should be given pre-operatively or
post-operatively, what might be the possible role of chemo-
therapy, and what the long-term results of the present study
might show and what therefore should be the appropriate
control group in the second study. It took three years before
a new trial was started. This was confined to tethered
tumours only and compared immediate surgery with a higher
dose of pre-operative radiotherapy, 4,000cGy in 20 fractions.
The predicted entry rate was 100 patients per year but only
40 patients per year have been achieved.
A study for mobile tumours, Dukes' B or C classification,
was not started until March 1984. This trial compared
immediately surgery with surgery plus post-operative radio-
therapy, and was expected to have an entry of 150 patients
per year. The entry achieved has been 100 per year.
There were four possible reasons why the rate of patient
entry was lower than expected. Firstly, the three-year gap
between the end of the first trial and the beginning of the
next obviously didn't help. Secondly, since no improvement
with pre-operative radiotherapy had been demonstrated in
the first trial, some surgeons were put off the idea of using
pre-operative radiotherapy again. Also, a third reason, the
longer period, 4 weeks, of pre-operative radiotherapy was
unpopular with surgeons. The fourth reason was uncertainty
whether it was sensible to sub-group patients into different
trials. The prognostic difference between mobile and tethered
tumours did not necessarily mean that radiotherapy would
be more beneficial in one sub-group than in the other.
Professor J. Peto strongly supported this last point. An
exactly similar mistake had, in his view, been made recently
in the MRC childhood leukaemia trials, where less intensive
treatment was being given to the minority of patients with
the better prognosis and, not randomised, but only giving
the most intensive treatment, with two lots of intensification,
to patients with the worse prognosis. This presupposes
knowledge which they do not have and now will not obtain
from the study.
The next speaker was C. Warlow (Oxford - but just
moved to Edinburgh) who spoke about his experience of
trials in neurology. In his specialty there were plenty of
burning questions: in the 1970's whether aspirin prevented
stroke, in the future the question of radiotherapy treatment
of gliomas, and at the moment whether a simple drug
treatment, Selegiline given once daily, can prevent or at least
reduce the development, or greater development of
Parkinson's disease.
The next requirement for large trials is to maximise the
number of collaborators. This will increase patient entry and
will also make the trial results more able to be generalised to
wider clinical practice. There is a problem in neurology in
that there are only about 200 neurologists in the UK. The
way to go is to extend into Europe where there are a few
thousand neurologists who have superb facilities and the
time to go to meetings and fill in protocols.
The grey area of uncertainty in clinicians' approaches
needs to be exploited. In the European trial on carotid
surgery for the prevention of stroke, clinicians differed as to
what degree of stenosis would make surgery absolutely
essential, and what was so minor that surgery would be
unethical. Their grey areas of uncertainty in between, where
they were willing to randomise patients, therefore covered
very different ranges of stenosis, but nevertheless their
patients could be combined in the same trial, and no
clinician had to be forced into procedures that he felt
unhappy about.
Prof. J. Peto asked what concrete change of policy did
people think the MRC and CRC could make which would
be beneficial in getting more patients entered into trials. One
suggestion he had made was that clinicians should only get
support for their research if their patients were being entered
into trials or were contributing to a central data bank.
Professor Baum felt that financial constraints were not now
so much of a problem as the ethical issues, although he
certainly thought that the MRC and the CRC should stop
funding small trials and concentrate their resources on large
ones. Professor Armitage asked if, in fact the MRC did
support many small trials.
Mr Freedman thought that the MRC could change its
policy in the way that trials are set up. At the moment there
is not a conscious effort to define important questions in
common cancers. Professor J. Peto emphasised this point by
stating that a collaborative group should be established to
study a disease rather than just to run a trial. Mr Freedman
said that the MRC did in fact set -up Working Parties in
particular diseases, but their membership was limited. A
Working Party was a small group of people who discussed
trials and other studies in that particular disease, but partici-
pants in those trials or studies would not necessarily be on
the Working Party, and might not therefore be involved in
discussion about the whole range of studies in that disease.
Professor Peto said that he had served on several MRC
Working Parties and he did not feel that they did study a
disease in the way that he had suggested. Mr Freedman felt
that it was a problem of some particular Working Parties
rather than the way in which they were set up by the MRC.
Professor Baum then mentioned the Breast Cancer Trials
Coordinating Committee funded by the MRC and the CRC.
This had played an important role in clarifying the
important questions in breast cancer. Similar Coordinating
Committees had already been started in colorectal cancer
and lung cancer. Prof. Armitage said that one shouldn't
forget that as long ago as the 1950s the MRC took the
initiative in setting up Working Parties to study the possi-
bilities of running clinical trials in various cancer sites.
Dr Aitken (MRC Head Office) explained that the Council
acknowledged the need for large multicentre trials. In order
to achieve adequate numbers of patients for cancer trials the
Cancer Therapy Committee was already undertaking some
joint studies with other groups such as the EORTC, and
collaborative links with the UK cancer charities were being
developed. However he emphasised that, particularly for the'
less common cancers, survival was not the only suitable
endpoint. It remained appropriate for the Council's Working
Parties to promote smaller trials in these diseases.
R. Collins (Oxford) gave the last paper in the afternoon
session. His subject was Acute Myocardial Infarction trials.
These trials had been designed to minimise work in order to
maximise trial size. The design was simple: testing practical
treatments, with only a one-page discharge form and follow-
up mainly through government records in those centres
where such records existed. The first study, ISIS 1, was a
study of beta-blockade given early in acute myocardial
infarction. The study, involving 250 hospitals worldwide and
16,000 randomised patients, demonstrated a reduction in
hospital mortality of 15%.
During the 3' years of recruitment into ISIS 1, the ISIS 2
trial was being planned. This study aimed to test the effect
of IV streptokinase on mortality after acute myocardial
infarction. First, an overview was made of all trials that had
been carried out in the past. The generally held view was
that streptokinase had no beneficial effect on mortality, andMEETING REPORT: CLINICAL TRIAL SIZE 525
that it might possibly be harmful since it reduced blood
clotting and might therefore increase the risk of
haemorrhage and stroke. The overview showed a clearly
significant reduction in mortality; typically the risk of death
in the treated group was reduced by about 20% with 95%
confidence interval from about 10% to 30%. Nevertheless it
was clear from the sales of streptokinase that it was not
being commonly used.
A similar overview of the randomised trials of aspirin in
unstable angina (which is a related condition to acute MI),
showed that death or re-infarction was 12% in the control
group compared with 7.5% in the aspirin treated group.
A 2 x 2 factorial design is therefore used. The treatments
tested are very simple: one involves a rapid high-dose
infusion of streptokinase given intravenously over one hour,
or placebo, and the second involves oral aspirin for a period
of one month. It should therefore be possible to assess the
effect of streptokinase, the effects of oral aspirin, and to find
out whether there is any synergistic effect between the two.
It is hoped that the target of about 20,000 patients will have
been achieved by the end of 1987.
Dr Kelly (Birmingham) said that what she found
depressing about the cancer trials was not only the small
numbers but also the very low proportion of patients
entering such trials. What proportion of all possibly eligible
patients were in the cardiovascular trials? Dr Collins said
that it was still only a few per cent. Dr Kelly said that rather
than stopping funding for inadequately sized trials, it seemed
more necessary to recruit the doctors who are not applying
for funds and are not entering patients for trials.
Mr R. Peto pointed out that there must be about a million
new cancer patients a year in Europe. It should therefore be
possible to recruit large numbers as in the cardiovascular
trials, if the right questions are asked. Dr Kelly said that
cancer is different in that it is many diseases, not one, and
that often cytotoxic drugs are used which may raise
problems in the smaller centres.
Professor Armitage then closed the meeting with a sum-
mary of what he felt had been the main points to emerge
during the day's proceedings.